版本:
中国

FDA approves Regeneron, Sanofi eczema drug

March 28 The U.S. Food and Drug Administration on Tuesday approved Regeneron Pharmaceuticals Inc and Sanofi SA's Dupixent for treatment of moderate to severe atopic dermatitis, a product widely seen as the most important future growth driver for the two companies.

Atopic dermatitis is a type of skin inflammation also known as eczema, which in severe cases causes intense constant itching.

(Reporting By Deena Beasley and Bill Berkrot; Editing by Chizu Nomiyama)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐